Preclinical Evidence and Mechanism of Xingnaojing Injection for Cerebral Ischemia: A Systematic Review and Meta‐Analysis of Animal Studies

Abstract

Objectives Cerebral ischemia can cause severe harm to people's health with the characteristics of high incidence, high disability, and high mortality. Xingnaojing injection (XNJI) is widely used in the treatment of cerebral ischemia. The aim of this review is to evaluate the efficacy and mechanism of XNJI in animal models of cerebral ischemia. Methods Total seven electronic databases in English or Chinese (CNKI, Wanfang, VMIS, PubMed, MEDLINE, Embase, and the Cochrane Library) about most experiments and studies which came out before June 2018 of XNJI for cerebral ischemia have been searched. Data extraction, quality assessment, and meta-analysis are conducted according to the Cochrane standards and RevMan 5.3 software. Results We have identified 23 eligible studies and made a meta-analysis based on these studies. Meta-analysis shows that XNJI contributes significantly to reduction in neurological deficit score (P = 0.0002, MD = −1.25, 95% CI: −1.92, −0.58) compared with the control group of cerebral ischemia. Subgroup analytic results demonstrate that XNJI has been more effective in animal model of cerebral ischemia-reperfusion injury (P = 0.009, MD = −1.35, 95%CI: −2.36, −0.34) than that of permanent cerebral ischemia (P = 0.0002, MD = −1.08, 95%CI: −1.66, −0.51). Compared with control group, XNJI could remarkably reduce cerebral infarction area (P < 0.00001, MD = −14.98, 95%CI: −21.36, −8.59), brain edema (P < 0.00001, MD = −4.64, 95%CI: −5.38, −3.90), and neuronal cell apoptosis (P < 0.0001, MD = −12.21, 95%CI: 18.05, −6.37). Meanwhile, the meta-analysis shows that XNJI has a significant anti-inflammatory effect, and the levels of TNF-α, IL-6, and IL-1β are significantly reduced by XNJI (P = 0.001, MD = −4.13, 95%CI:−6.68, −1.58; P < 0.00001, MD = −119.23, 95%CI: −138.04, −100.43; P = 0.21, MD = −228.69, 95% CI: −586.20, 128.83). Additionally, XNJI could raise the body's antioxidant function and the level of SOD and GSH-Px (P = 0.002, MD = 53.02, 95% CI: −20.52, 85.78; P = 0.01, MD = 8.65, 95% CI: 1.77, 15.48) and decrease the level of MDA (P < 0.00001, MD = −4.16, 95% CI: −5.50, −2.82). Conclusion XNJI might be effective in cerebral ischemia by regulating oxidative stress and inflammatory reaction.

l-Borneol Exerted the Neuroprotective Effect by Promoting Angiogenesis Coupled With Neurogenesis via Ang1-VEGF-BDNF Pathway

“…Borneol is a traditional Chinese medicine, which has the effect of resuscitation and restoring the spirit. The Chinese patent medicine containing borneol is commonly used in the treatment of cerebrovascular diseases, and even has better therapeutic effect than other therapies ( Liu et al, 2019 ; Ma et al, 2018 and 2017 ). L- borneol comes from Blumea balsamiera (L.) DC, which is safe and easy to obtain ( Luo et al, 2018 ).…”

What has preclinical systematic review ever done for us?

“…On inspection of these papers, we found 283 papers examining therapeutic interventions in preclinical disease models. We selected 20 of these at random for closer examination, [12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31] their characteristics are summarised in table 1.…”

Clinical Progress on Management of Pneumonia Due to COVID-19 With Chinese Traditional Patent Medicines

“…It has been widely used for intracerebral hemorrhage, brain ischemia, and other neurological diseases ( Zhang S. et al, 2017 ). In vitro experiments showed that the therapeutic effect on loss of consciousness is due to its anti-neurotoxicity induced by excitatory amino acids, radical scavenging, cytokine suppressing, and apoptosis related gene regulating characters ( Ma et al, 2018 ). It can be used for COVID-19 patients with high fever and disturbance in consciousness, but there is no such report.…”